Literature DB >> 8139258

Kinetic expression of endothelial adhesion molecules and relationship to leukocyte recruitment in two cutaneous models of inflammation.

A Silber1, W Newman, K A Reimann, E Hendricks, D Walsh, D J Ringler.   

Abstract

BACKGROUND: Adhesive interactions between circulating leukocytes and endothelium is requisite for subsequent leukocyte extravasation at inflammatory sites. These adhesive events are mediated by a repertoire of proteins and carbohydrate moieties on both leukocyte and endothelial membranes. Understanding the kinetic expression of these adhesion molecules during an inflammatory cascade in vivo is important for the design and testing of rational therapeutic approaches directed at the blockade of adhesion molecule function in inflammatory disease. EXPERIMENTAL
DESIGN: Two cutaneous inflammatory models were examined using healthy rhesus monkeys. Acute cutaneous injury was studied during a 72-hour period by intradermal injection of endotoxin (lipopolysaccharide) and subsequent biopsy. These tissues were then compared with those obtained from a cutaneous delayed-type hypersensitivity reaction (DHR), elicited by intradermal injections of mammalian tuberculin in sensitized animals and followed for up to 11 days. Expression of E-selectin, P-selectin, VCAM-1, and ICAM-1 was assessed using immunohistochemistry and compared with leukocyte localization and immunohistochemical expression of interleukin (IL) 1, IL-8 and tumor necrosis factor-alpha (TNF-alpha). Finally, relevant adhesion ligands on leukocytes were assessed using flow cytometry.
RESULTS: The lipopolysaccharide model was characterized by early (0.5 hours) and sustained (up to 72 hours) expression of E-selectin on the superficial dermal vasculature, with maximal expression by 8 hours. The expression of VCAM-1 was either not detected or minimal. Neutrophil localization, as detected by elastase immunoreactivity, paralleled E-selectin expression with a 4- to 12-hour lag phase, being maximal by 24 hours. In contrast, DHR was characterized by the dual asynchronous expression of both E-selectin and VCAM-1. Localization of CD2+ lymphocytes, representing the predominant cell type recruited, kinetically followed the expression of E-selectin and VCAM-1, being maximal in number at approximately 48 hours after peak expression of both of these endothelial proteins. Neutrophil recruitment in lipopolysaccharide-induced injury was associated with immunohistochemical localization of TNF-alpha, IL-1, and IL-8, whereas only TNF-alpha was consistently detected in DHR. During DHR, blood lymphocyte expression of L-selectin, VLA-4 (CD49d; alpha chain), and lymphocyte function-associated antigen 1 (both CD11a (alpha chain) and CD18 (beta chain)) did not change.
CONCLUSIONS: The results from this study demonstrate that cutaneous inflammatory infiltrates of varying cellular compositions are associated temporally and spatially with unique patterns of endothelial adhesion molecule and cytokine expression.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8139258

Source DB:  PubMed          Journal:  Lab Invest        ISSN: 0023-6837            Impact factor:   5.662


  13 in total

1.  Inhibition of T cell recruitment and cutaneous delayed-type hypersensitivity-induced inflammation with antibodies to monocyte chemoattractant protein-1.

Authors:  M L Rand; J S Warren; M K Mansour; W Newman; D J Ringler
Journal:  Am J Pathol       Date:  1996-03       Impact factor: 4.307

2.  Cell-Specific Variation in E-Selectin Ligand Expression among Human Peripheral Blood Mononuclear Cells: Implications for Immunosurveillance and Pathobiology.

Authors:  Mariana Silva; Ronald Kam Fai Fung; Conor Brian Donnelly; Paula Alexandra Videira; Robert Sackstein
Journal:  J Immunol       Date:  2017-03-22       Impact factor: 5.422

3.  Tumor necrosis factor-alpha mediates diabetes-enhanced apoptosis of matrix-producing cells and impairs diabetic healing.

Authors:  Rongkun Liu; Harbinder S Bal; Tesfahun Desta; Yugal Behl; Dana T Graves
Journal:  Am J Pathol       Date:  2006-03       Impact factor: 4.307

4.  Human mucosal addressin cell adhesion molecule-1 is preferentially expressed in intestinal tract and associated lymphoid tissue.

Authors:  M Briskin; D Winsor-Hines; A Shyjan; N Cochran; S Bloom; J Wilson; L M McEvoy; E C Butcher; N Kassam; C R Mackay; W Newman; D J Ringler
Journal:  Am J Pathol       Date:  1997-07       Impact factor: 4.307

5.  Interferon-gamma up-regulates intercellular adhesion molecule-1 and vascular cell adhesion molecule-1 and recruits lymphocytes into the vagina of immune mice challenged with herpes simplex virus-2.

Authors:  M B Parr; E L Parr
Journal:  Immunology       Date:  2000-04       Impact factor: 7.397

6.  Pediatric AIDS-associated lymphocytic interstitial pneumonia and pulmonary arterio-occlusive disease: role of VCAM-1/VLA-4 adhesion pathway and human herpesviruses.

Authors:  S J Brodie; C de la Rosa; J G Howe; J Crouch; W D Travis; K Diem
Journal:  Am J Pathol       Date:  1999-05       Impact factor: 4.307

7.  Digibind attenuates cytokine TNFalpha-induced endothelial inflammatory response: potential benefit role of digibind in preeclampsia.

Authors:  Y Wang; D F Lewis; C D Adair; Y Gu; L Mason; J H Kipikasa
Journal:  J Perinatol       Date:  2009-01-15       Impact factor: 2.521

Review 8.  Targeting selectins and selectin ligands in inflammation and cancer.

Authors:  Steven R Barthel; Jacyln D Gavino; Leyla Descheny; Charles J Dimitroff
Journal:  Expert Opin Ther Targets       Date:  2007-11       Impact factor: 6.902

9.  Replacing the Promoter of the Murine Gene Encoding P-selectin with the Human Promoter Confers Human-like Basal and Inducible Expression in Mice.

Authors:  Zhenghui Liu; Nan Zhang; Bojing Shao; Sumith R Panicker; Jianxin Fu; Rodger P McEver
Journal:  J Biol Chem       Date:  2015-12-02       Impact factor: 5.157

10.  Differential regulation of human and murine P-selectin expression and function in vivo.

Authors:  Zhenghui Liu; Jonathan J Miner; Tadayuki Yago; Longbiao Yao; Florea Lupu; Lijun Xia; Rodger P McEver
Journal:  J Exp Med       Date:  2010-12-13       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.